Imlifidase specifically targets IgG and inhibits pathogenic IgG-mediated immune responses in transplant patients and patients with autoimmune disease or cancer. Imlifidase infusion has a better safety profile than plasmapheresis, and three patients in a clinical phase II trial received two doses within a 24-hour period without experiencing allergic reactions. Imlifidase is currently approved for sensitized transplant candidates in the European Union who are receiving organs from deceased donors, but it is under consideration as a treatment for patients receiving organs from living donors.
PharmD – Scientific Affairs Director
Oct 27, 2021
Please sign in to access your account. Customers must log in to access some content, recorded webinars, training materials, documents, and software.
Please provide the following to setup your user account. If you do not know your center ID, please leave the center ID field blank.
Passwords do not match